Innate Pharma Statistics
Total Valuation
Innate Pharma has a market cap or net worth of 216.75 million. The enterprise value is 158.66 million.
| Market Cap | 216.75M |
| Enterprise Value | 158.66M |
Important Dates
The next estimated earnings date is Wednesday, September 17, 2025.
| Earnings Date | Sep 17, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
| Current Share Class | 92.17M |
| Shares Outstanding | n/a |
| Shares Change (YoY) | +0.74% |
| Shares Change (QoQ) | +0.44% |
| Owned by Insiders (%) | n/a |
| Owned by Institutions (%) | n/a |
| Float | 59.22M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | 8.25 |
| PS Ratio | 10.41 |
| PB Ratio | 23.70 |
| P/TBV Ratio | 23.70 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -3.10 |
| EV / Sales | 6.76 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | -21.03 |
Financial Position
The company has a current ratio of 2.60, with a Debt / Equity ratio of 3.51.
| Current Ratio | 2.60 |
| Quick Ratio | 2.50 |
| Debt / Equity | 3.51 |
| Debt / EBITDA | n/a |
| Debt / FCF | -4.25 |
| Interest Coverage | -91.12 |
Financial Efficiency
Return on equity (ROE) is -162.91% and return on invested capital (ROIC) is -48.98%.
| Return on Equity (ROE) | -162.91% |
| Return on Assets (ROA) | -22.52% |
| Return on Invested Capital (ROIC) | -48.98% |
| Return on Capital Employed (ROCE) | -66.06% |
| Revenue Per Employee | 115,090 |
| Profits Per Employee | -282,970 |
| Employee Count | 181 |
| Asset Turnover | 0.14 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -1.93% in the last 52 weeks. The beta is 0.93, so Innate Pharma's price volatility has been similar to the market average.
| Beta (5Y) | 0.93 |
| 52-Week Price Change | -1.93% |
| 50-Day Moving Average | 2.45 |
| 200-Day Moving Average | 3.45 |
| Relative Strength Index (RSI) | 49.50 |
| Average Volume (20 Days) | 1,573 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Innate Pharma had revenue of 20.83 million and -51.22 million in losses. Loss per share was -0.63.
| Revenue | 20.83M |
| Gross Profit | -32.98M |
| Operating Income | -53.40M |
| Pretax Income | -51.22M |
| Net Income | -51.22M |
| EBITDA | -52.05M |
| EBIT | -53.40M |
| Loss Per Share | -0.63 |
Balance Sheet
The company has 83.62 million in cash and 32.09 million in debt, giving a net cash position of 51.53 million.
| Cash & Cash Equivalents | 83.62M |
| Total Debt | 32.09M |
| Net Cash | 51.53M |
| Net Cash Per Share | n/a |
| Equity (Book Value) | 9.15M |
| Book Value Per Share | 0.11 |
| Working Capital | 54.62M |
Cash Flow
In the last 12 months, operating cash flow was -7.14 million and capital expenditures -404,804, giving a free cash flow of -7.54 million.
| Operating Cash Flow | -7.14M |
| Capital Expenditures | -404,804 |
| Free Cash Flow | -7.54M |
| FCF Per Share | n/a |
Margins
Gross margin is -158.34%, with operating and profit margins of -256.32% and -245.87%.
| Gross Margin | -158.34% |
| Operating Margin | -256.32% |
| Pretax Margin | -245.87% |
| Profit Margin | -245.87% |
| EBITDA Margin | -249.86% |
| EBIT Margin | -256.32% |
| FCF Margin | n/a |
Dividends & Yields
Innate Pharma does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -0.74% |
| Shareholder Yield | -0.74% |
| Earnings Yield | -23.63% |
| FCF Yield | -3.48% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Innate Pharma has an Altman Z-Score of -4.65 and a Piotroski F-Score of 2. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -4.65 |
| Piotroski F-Score | 2 |